1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Long-term safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase III trials

      EMJ Dermatol

      Read this article at

      ScienceOpen
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Comments

          Comment on this article